SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on June 19, 2012. The filing discloses a material definitive agreement regarding a public offering of common stock and a corporate amendment to effect a reverse stock split. Note: The request metadata referenced "Riot Platforms, Inc.," but the source text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics and Transaction Details
- Offering Size: 6,100,000 shares of common stock.
- Public Offering Price: $2.00 per share.
- Underwriting Price: $1.86 per share.
- Expected Net Proceeds: Approximately $10.8 million (after discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 915,000 additional shares at the same price.
- Warrants Issued: 305,000 warrants to the representative, exercisable from June 19, 2013, to June 19, 2017, at an exercise price of $2.50 per share.
- Reverse Stock Split: A 6-for-1 reverse stock split was effected, effective June 20, 2012. Fractional shares are rounded up to the nearest whole share.
Material Changes and Corporate Actions
The primary material change is the entry into an underwriting agreement with Aegis Capital Corp. for a firm commitment public offering. Concurrently, the Company amended its Articles of Incorporation to implement a 6-for-1 reverse stock split. Trading on the NASDAQ Capital Market began on a split-adjusted basis on June 20, 2012. The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The closing of the offering is expected on June 25, 2012, subject to customary closing conditions. As part of the underwriting agreement, all officers and directors have entered into lock-up agreements prohibiting the sale or transfer of Company securities for 90 days following June 19, 2012. The filing includes customary indemnification provisions and representations. No specific forward-looking guidance on revenue or operational milestones is provided in this text.
Key Facts for Investor Verification
- Verify the actual closing date of the offering (expected June 25, 2012) and the final net proceeds received.
- Confirm the post-split share count and the impact of the 6-for-1 reverse split on existing holdings.
- Monitor the exercise of the 45-day over-allotment option by underwriters.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification details.
- Check subsequent filings for the utilization of the $10.8 million in expected proceeds.